Search

Displaying results 2961 - 2970 of 8517 in total
  1. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    Initially, it was marketed in 1995 under the trade name, _Landel_. The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. … It has also been studied in atherosclerosis and acute renal failure [A32001]. This drug is also known as NZ-105, and several studies have been done on its pharmacokinetics in animals [L1456].

  2. Drug

    Amolimogene bepiplasmid

    go.drugbank.com/drugs/DB04904
    Investigational

    Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.

  3. Drug

    QR-333

    go.drugbank.com/drugs/DB05533
    Investigational

    QR-333 has been investigated as a treatment for diabetic peripheral neuropathy.

  4. Drug

    Recombinant alpha 1-antitrypsin

    go.drugbank.com/drugs/DB05481
    Investigational

    kallikrein, as well as neutrophil elastase. … The company has indicated that other formulations for gastroenterological and urological indications will also be developed.

  5. Drug

    Nialamide

    go.drugbank.com/drugs/DB04820
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

  6. Drug

    Itraconazole

    go.drugbank.com/drugs/DB01167
    ApprovedInvestigational

    While the intravenous formulation of the drug was formerly available, it was discontinued in the US in 2007.[A263232] … [L50051] Itraconazole was first approved in the US in 1992 [L50056] and is available orally.

  7. Drug

    Chlorprothixene

    go.drugbank.com/drugs/DB01239
    ApprovedInvestigationalWithdrawn

    Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.

  8. Drug

    Fasinumab

    go.drugbank.com/drugs/DB12157
    Investigational

    [A241165] NGF was first discovered in the 1950s[A241180] and was the first neurotrophic factor to be identified and biochemically characterized. … [A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions.

  9. Drug

    Carmofur

    go.drugbank.com/drugs/DB09010
    ApprovedWithdrawn

    Carmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy.

  10. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses.